Welcome to our dedicated page for CapsoVision news (Ticker: CV), a resource for investors and traders seeking the latest updates and insights on CapsoVision stock.
CapsoVision, Inc. (NASDAQ: CV) is a commercial-stage medical technology company that regularly issues news and updates related to its advanced imaging and AI-enabled capsule endoscopy solutions for gastrointestinal disease detection. This news page aggregates company press releases and market announcements so readers can follow developments around its medical devices and regulatory progress.
CapsoVision’s news flow often covers topics such as performance of its flagship CapsoCam Plus capsule endoscopy system for small bowel visualization, including adoption trends and usage metrics disclosed in quarterly financial results. The company also reports on regulatory milestones, for example submissions of 510(k) applications to the U.S. Food and Drug Administration for its AI-assisted reading module for CapsoCam Plus and for CapsoCam Colon, a capsule designed for non-invasive colon imaging and polyp detection.
Investors and healthcare professionals can also find updates on CapsoVision’s efforts to expand its capsule platform into new indications. These include its application for Breakthrough Device Designation for the CapsoCam UGI capsule endoscopy system for potential early-stage pancreatic cancer detection, as well as broader plans to address multiple GI indications, including esophageal and pancreatic disorders.
In addition, CapsoVision uses news releases to communicate quarterly financial results, participation in investor conferences, and changes in its leadership team, such as executive appointments and transitions. By reviewing the items on this page, readers can track how CapsoVision is advancing its AI-enabled capsule endoscopy portfolio, progressing through regulatory pathways, and managing its public company responsibilities. For ongoing insight into CV-related announcements, this page provides a centralized view of the company’s official news.
CapsoVision (NASDAQ: CV) reported fourth-quarter revenue of $3.9 million (+13% YoY) and full-year 2025 revenue of $13.6 million (+15% YoY). Gross profit for 2025 was $7.2 million with a 53% full-year gross margin. Operating expenses rose to $32.7 million, up $6.4 million year-over-year. Cash and cash equivalents were $10.1 million at year-end. The company submitted a 510(k) for an AI-assisted module for CapsoCam Plus and completed a $14 million private placement on March 16, 2026, after an IPO in July 2025.
CapsoVision (NASDAQ: CV) closed a $14.0 million private placement on March 16, 2026, selling 2,867,089 shares at $4.883 per share (5% discount to the March 16 close).
Net proceeds will fund sales, R&D, G&A and working capital. Preliminary Q4 revenue was $3.9M, full-year 2025 revenue $13.6M, and cash and investments were approximately $10.1M as of December 31, 2025. Registration rights require a resale registration statement within 90 days; full audited results and a webcast are scheduled for March 26, 2026.
CapsoVision (NASDAQ: CV) will release fourth quarter and full year 2025 financial results on Thursday, March 26, 2026, after market close.
The company will host a conference call and live webcast on March 26, 2026 at 1:30 pm PT / 4:30 pm ET to discuss results and provide a corporate update. Dial-in numbers: (800) 715-9871 (US) or (646) 307-1963 (international); conference ID 2525025. The webcast replay will be available for one year via the Events page in investor relations; registration required to access the replay.
CapsoVision (NASDAQ: CV) will present at the 38th Annual ROTH Conference on Monday, March 23, 2026 in Dana Point, CA. Management will host a fireside chat and hold 1x1 investor meetings at 10:30–10:55 am PT.
The fireside chat will be webcast live and archived on the company Events page for one year; investors can request one-on-one meetings via their Roth representative or Investors@CapsoVision.com.
CapsoVision (NASDAQ: CV) submitted a 510(k) to the U.S. Food and Drug Administration on Dec. 29, 2025 for an AI-assisted reading module for its CapsoCam Plus capsule endoscopy system.
The module is intended to improve detection of clinically significant small-bowel pathology and reduce clinician review time. The company said it plans to begin U.S. commercialization after FDA clearance. CapsoCam Plus is indicated for visualization of the small bowel mucosa in adults and children aged two years and older.
CapsoVision highlighted in-house AI capabilities, a growing image data set for model training, and a fully cloud-based architecture intended to remove on-site servers and reduce IT maintenance.
CapsoVision (NASDAQ: CV) announced that senior management will participate in the Benchmark 14th Annual Discovery One-on-One Investor Conference on December 4, 2025 in New York City.
Attending executives include Johnny Wang, President and CEO; David Garcia, SVP Finance; and Doug Atkinson, SVP Global Sales. Investors seeking a one-on-one meeting are asked to contact their Benchmark representative or email Investors@CapsoVision.com.
CapsoVision (NASDAQ: CV) reported third quarter 2025 results for the period ended September 30, 2025. Q3 revenue was $3.5 million, a 19% increase year‑over‑year, driven by higher CapsoCam Plus capsule sales and new accounts up 31%. Gross profit rose to $1.9 million (up $0.3 million; 54% gross margin). Operating expenses increased to $9.9 million, reflecting R&D with Canon, higher G&A costs and public‑company expenses. Cash and cash equivalents totaled $17.8 million; the company completed an IPO in July 2025 with $23.4 million net proceeds. The company filed for Breakthrough Device Designation for an early pancreatic cancer capsule and began enrollment for a new colon‑capsule study.
CapsoVision (NASDAQ: CV) announced it submitted a Breakthrough Device Designation (BDD) application to the FDA on Nov 6, 2025 for its CapsoCam UGI capsule endoscopy system to support earlier detection of pancreatic ductal adenocarcinoma.
The non-invasive, swallowed capsule provides panoramic imaging to visualize the duodenal papilla, a potential early indicator of pancreatic abnormalities, and streams images to a secure cloud for physician review. The company said the BDD could accelerate development, help shape clinical studies, and speed regulatory review.
The release highlights pancreatic cancer's poor prognosis (five-year survival as low as 8–10%), that ~80% of diagnoses occur at advanced stages, and the absence of recommended non-invasive screening for the general population.
CapsoVision (NASDAQ: CV) announced the appointment of David Garcia as Senior Vice President of Finance, effective November 3, 2025. Garcia brings more than 20 years of finance leadership across corporate finance, capital markets and strategic transactions.
His prior roles include Vice President of Financial Planning and Analysis at Matterport, where he helped lead its initial public offering and supported a recent acquisition, plus senior finance positions at View, Intelepeer Cloud Communications, and Align Technology, and earlier roles at Oracle and Deloitte. Management says his capital markets and cash-management experience will support CapsoVision's development pipeline and disciplined growth. Garcia holds an MBA in Finance from Wharton and a BA in Economics from Stanford.
CapsoVision (NASDAQ: CV) will release its third quarter 2025 financial results on Thursday, November 13, 2025 after market close. The company will host a conference call and live webcast on the same day at 1:30 pm PT / 4:30 pm ET to discuss results and provide a corporate update.
Dial-in details: domestic (800) 715-9871, international (646) 307-1963, conference ID 2181260. The webcast link and replay registration are available on the Events page in the investor relations section of the company website. The webcast replay will remain available for one year following the call.